Washington-based AGC Biologics has been chosen to help manufacture Provention Bio’s Type 1 juvenile diabetes treatment. The treatment had been in development for over 36 years prior to receiving FDA approval late last year.
AGC Biologics, which has produced biologics for 30 years, will develop Tzield (teplizumab-mzwv) at the Seattle protein biologics facility.
“This is an important milestone for the Type 1 diabetes community, and we hope the launch of this therapy can truly make an impact on patients and families seeking innovative treatments for the delay of Stage 3 T1D,” said Ashleigh Palmer, Provention Bio’s chief executive.